Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05237258 · ClinicalTrials.gov registry record · NA

Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia

A NA study of High Risk Acute Myeloid Leukemia and Relapsed Adult AML, sponsored by Massachusetts General Hospital.

Recruiting
Registry status
NA
Development phase
2,300
Enrollment target
20
Study locations

NCT05237258: Recruiting NA study of High Risk Acute Myeloid Leukemia and Relapsed Adult AML, sponsored by Massachusetts General Hospital.

NCT05237258 is a NA study of High Risk Acute Myeloid Leukemia and Relapsed Adult AML that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 2,300 participants, above the 203-participant average among 4 other High Risk Acute Myeloid Leukemia trials with a reported enrollment target (1033% higher). The trial reports 20 study locations across 17 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05237258, a NA study of High Risk Acute Myeloid Leukemia and Relapsed Adult AML, is actively recruiting participants, sponsored by Massachusetts General Hospital.

RECRUITING
Registry status
NA
Development phase
2,300 participants
Enrollment target
20
Study locations

Study Summary

This research study is evaluating whether primary palliative care is an alternative strategy to specialty palliative care for improving quality of life, symptoms, mood, coping, and end of life outcomes in patients with acute myeloid leukemia (AML).

Primary Outcome

Establish that primary palliative care is non-inferior to specialty palliative care in patient-reported quality of life (QOL) as measured by the Functional Assessment of Cancer Therapy-Leukemia (FACT-Leukemia) over 12 weeks. Higher scores on FACT-Leukemia (range 0-176) indicate a better QOL.

Interventions

  • BEHAVIORAL Specialty Palliative Care
  • BEHAVIORAL Primary Palliative Care

Study Locations (20)

Florida

  • University of Miami - Miami
  • Moffitt Cancer Center - Tampa

Massachusetts

  • Massachusetts General Hospital - Boston
  • Dana-Farber Cancer Institute - Boston

North Carolina

  • University of North Carolina at Chapel Hill - Chapel Hill
  • Duke University - Durham

Alabama

  • University of Alabama - Birmingham - Birmingham

California

  • Stanford University - Stanford

Colorado

  • University of Colorado Denver I Anschutz Medical Campus - Denver

Georgia

  • Emory University - Atlanta

Illinois

  • Northwestern University - Evanston

Trial Details

FieldValue
Enrollment Target 2,300 participants
Start Date 2022-06-01
Est. Completion 2029-04
Phase NA
Massachusetts General Hospital

2,032 total trials

What NCT05237258 shows while recruiting

NCT05237258 is an interventional study that assigns participants to a tested intervention. Its 2,300 participants enrollment target places it among the larger protocols in the corpus, above the 203-participant average among 4 other High Risk Acute Myeloid Leukemia trials with a reported enrollment target (1033% higher).

The record links to 3 conditions, with High Risk Acute Myeloid Leukemia appearing as the primary indexed condition, and to 2 interventions - of which Specialty Palliative Care is the first listed.

NCT05237258 names 20 study sites across 17 states, led by Florida, Massachusetts, North Carolina.

Frequently Asked Questions

What is clinical trial NCT05237258 about?

NCT05237258 is a clinical study titled "Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia". This research study is evaluating whether primary palliative care is an alternative strategy to specialty palliative care for improving quality of life, symptoms, mood, coping, and end of life outcomes in patients with acute myeloid leukemia (AML).

What is the current status of trial NCT05237258?

This trial is currently recruiting. It is a NA study. The enrollment target is 2,300 participants. The study started on 2022-06-01. Estimated completion is 2029-04.

What conditions does trial NCT05237258 study?

This clinical trial studies the following conditions: High Risk Acute Myeloid Leukemia, Relapsed Adult AML, Primary Refractory Acute Myeloid Leukemia.

What interventions are being tested in trial NCT05237258?

The interventions under investigation include: Specialty Palliative Care (BEHAVIORAL), Primary Palliative Care (BEHAVIORAL).

Who is sponsoring clinical trial NCT05237258?

This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05237258 being conducted?

This trial has 20 study locations across Alabama, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for High Risk Acute Myeloid Leukemia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04124120 · 2,300 participants · NA

    Comparison of the Outcomes of Single vs Multiple Arterial Grafts in Women

  • NCT05732623 · 2,300 participants

    Exogenous and Endogenous Risk Factors for Early-onset Colorectal Cancer

  • NCT05759988 · 2,300 participants · NA

    Cervical Ripening as an Outpatient Method Using the Foley (COMFORT)

  • NCT05964010 · 2,300 participants · NA

    Primary Connections for Youth and Families

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05237258, the US trial registry maintained by the National Library of Medicine. NCT05237258 (large enrollment · wide site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.